Mirum names Rob Myers as CMO, succeeding Joanne Quan
Mirum Pharmaceuticals disclosed a Chief Medical Officer transition, with Myers' start and Quan's separation both described as expected rather than final.
SEC filing
Latest
4 stories
Wednesday, September 16
Tuesday, September 8
Wednesday, August 5
Mirum raises 2026 sales guidance, volixibat gets FDA breakthrough status for PSC
The company also disclosed the FDA wants a Phase 3 study before a volixibat NDA, pushing the target filing to the first half of 2027.
SEC filing